{
    "organizations": [],
    "uuid": "96ff0d95caed44c00b2a04ef6c5fdf41cb534494",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-chemocentryx-q1-revenue-95-million/brief-chemocentryx-q1-revenue-9-5-million-versus-8-2-million-idUSASC0A14K",
    "ord_in_thread": 0,
    "title": "BRIEF-Chemocentryx Q1 Revenue $9.5 Million Versus $8.2 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9 (Reuters) - ChemoCentryx Inc:\n* CHEMOCENTRYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS\n* Q1 REVENUE VIEW $7 MILLION — THOMSON REUTERS I/B/E/S * EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MILLION AND $75 MILLION FOR TWELVE MONTHS ENDING DECEMBER 31, 2018\n* QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19 * Q1 EARNINGS PER SHARE VIEW $-0.23 — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T04:17:00.000+03:00",
    "crawled": "2018-05-10T17:48:59.041+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "chemocentryx",
        "inc",
        "chemocentryx",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "recent",
        "highlight",
        "q1",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "expects",
        "utilize",
        "cash",
        "investment",
        "million",
        "million",
        "twelve",
        "month",
        "ending",
        "december",
        "qtrly",
        "diluted",
        "net",
        "loss",
        "per",
        "common",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}